Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

ShedRx vs Modern Age

Two GLP-1 desks, one scoreboard. We put ShedRx and Modern Age head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →
vs
No. 392 · Grade C

Modern Age

Visit Modern Age Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 56 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make Modern Age a bad call — it's best for patients wanting a premium, branded-glp-1 weight program inside a longevity clinic. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
86
52
Supply Reliability
86
69
Transparency
84
24
Access Breadth
85
46
Clinical Oversight
85
83
Track Record
86
75
ShedRxBrief Score 87 · 56Modern Age

Price, coverage & the tracker

ShedRxModern Age
Brief Score87/100 (B+)56/100 (C)
Semaglutide$199/moFrom $900/mo (all doses, medication billed separately, brand-name)
Tirzepatide$299/moNot disclosed
CoverageNot disclosedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
On the trackerFallingprice fallingNewnew to the tracker, no prior reading

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

Modern Age: New to the tracker on 1 August 2026. The published line reads From $900/mo (all doses, medication billed separately, brand-name) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.